# US 2025/0052759 A1 · Biomarkers and methods of treating pd-1 and pd-l1 related conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0052759 A1
- Document ID: US20250052759A1
- Status: Published application
- Kind: A1
- Application number: 18/933,358
- Filed: 2024-10-31
- Published: 2025-02-13
- Earliest claimed: 2013-03-15
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Marcin Kowanetz; Daniel Shin-Yu Chen; Hartmut Koeppen
- Web page: https://patentgrep.com/patent/US20250052759A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/30: from tumour cells
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/575: for cancer
- G06Q 30/0241: Advertisements
- G06Q 30/0251: Targeted advertisements
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/70532: B7 molecules, e.g. CD80, CD86
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G06Q: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR

## Abstract

Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

## Claims

### Claim 1

A method for treating a cancer in an individual comprising administering to the individual an effective amount of an anti-PD-L1 antibody every three weeks, wherein the anti-PD-L1 antibody comprises the following hypervariable regions (HVRs):
(SEQ ID NO: 15)
(a) an HVR-H1 sequence of GFTFSDSWIH;
(SEQ ID NO: 16)
(b) an HVR-H2 sequence of AWISPYGGSTYYADSVKG;
(SEQ ID NO: 3)
(c) an HVR-H3 sequence of RHWPGGFDY;
(SEQ ID NO: 17)
(d) an HVR-L1 sequence of RASQDVSTAVA;
(SEQ ID NO: 18)
(e) an HVR-L2 sequence of SASFLYS;
and
(SEQ ID NO: 19)
(f) an HVR-L3 sequence of QQYLYHPAT.

### Claim 2 (depends on 1)

The method of claim 1, wherein the effective amount of the anti-PD-L1 antibody is about 15 mg/kg, about 20 mg/kg, or about 30 mg/kg.

### Claim 3 (depends on 1)

The method of claim 1, wherein the effective amount of the anti-PD-L1 antibody is about 1200 mg.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is a lung cancer, a kidney cancer, a colorectal cancer, an ovarian cancer, a breast cancer, a pancreatic cancer, a liver cancer, a gastric carcinoma, a bladder cancer, an esophageal cancer, a skin cancer, a head and neck cancer, a sarcoma, a prostate cancer, a cervical cancer, thymic carcinoma, or a hematologic malignancy.

### Claim 5 (depends on 4)

The method of claim 4, wherein:
(a) the cancer is a lung cancer, and wherein the lung cancer is a non-small cell lung cancer or a small cell lung cancer;
(b) the cancer is a skin cancer, and wherein the skin cancer is a melanoma or a Merkel cell cancer;
(c) the cancer is a breast cancer, and wherein the breast cancer is a triple-negative breast cancer;
(d) the cancer is a bladder cancer, and wherein the bladder cancer is a urothelial bladder cancer;
(e) the cancer is a hematologic malignancy, and wherein the hematologic malignancy is a lymphoma, a myeloma, or a mycosis fungoides;
(f) the cancer is a kidney cancer, and wherein the kidney cancer is a renal cell carcinoma;
(g) the cancer is a colorectal cancer, and wherein the colorectal cancer is a locally advanced or metastatic colorectal cancer;
(h) the cancer is a gastric cancer, and wherein the gastric cancer is a locally advanced or metastatic gastric cancer, or
(i) the cancer is a liver cancer, and wherein the liver cancer is a hepatocellular cancer or a hepatic carcinoma.

### Claim 6 (depends on 5)

The method of claim 5, wherein:
(a) the lung cancer is a non-small cell lung cancer, and wherein the non-small cell lung cancer is a locally advanced or metastatic non-small cell lung cancer;
(b) the skin cancer is a melanoma, and wherein the melanoma is a locally advanced or metastatic melanoma;
(c) the breast cancer is a triple-negative breast cancer, and wherein the triple-negative breast cancer is unresectable;
(d) the bladder cancer is a urothelial bladder cancer, and wherein the urothelial bladder cancer is a metastatic urothelial bladder cancer;
(e) the kidney cancer is a renal cell carcinoma, and wherein the renal cell carcinoma is a locally advanced or metastatic renal cell carcinoma, or
(f) the liver cancer is a hepatocellular cancer or a hepatic carcinoma, and wherein the hepatocellular cancer or hepatic carcinoma is a locally advanced or metastatic hepatocellular cancer or hepatic carcinoma.

### Claim 7 (depends on 1)

The method of claim 1, wherein the anti-PD-L1 antibody is administered to the individual in combination with an effective amount of an additional therapeutic agent or an adjuvant.

### Claim 8 (depends on 7)

The method of claim 7, wherein:
(a) the additional therapeutic agent is a cytotoxic agent, a chemotherapeutic agent, a growth inhibitory agent, a radiation therapy agent, or an anti-angiogenic agent; or
(b) the adjuvant is a chemotherapeutic agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the chemotherapeutic agent or the adjuvant is a platinum-based chemotherapeutic agent.

### Claim 10 (depends on 7)

The method of claim 7, wherein:
(a) the additional therapeutic agent is carboplatin, etoposide, paclitaxel, or albumin-engineered nanoparticle formulation of paclitaxel (nab-paclitaxel); or
(b) the adjuvant is cisplatin.

### Claim 11 (depends on 1)

The method of claim 1, wherein the anti-PD-L1 antibody is MPDL3280A.

### Claim 12 (depends on 1)

The method of claim 1, wherein the anti-PD-L1 antibody is administered intravenously.

### Claim 13 (depends on 1)

The method of claim 1, wherein prior to administration of the anti-PD-L1 antibody, the individual has been determined to be an individual who is likely to have an increased clinical benefit from treatment with an anti-PD-L1 antibody based on the presence of a detectable expression level of PD-L1 protein in tumor infiltrating immune cells covering >10% of tumor area in a tumor tissue sample obtained from the individual.

### Claim 14 (depends on 13)

The method of claim 13, wherein the increased clinical benefit comprises a relative increase in one or more of the following: objective response rate (ORR), overall survival (OS), progression free survival (PFS), complete response (CR), partial response (PR), or a combination thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the increased clinical benefit comprises a relative increase in ORR.

### Claim 16 (depends on 13)

The method of claim 13, wherein PD-L1 protein is detected in the tumor tissue sample using immunohistochemistry (IHC), immunofluorescence, radioimmunoassay, immunodetection methods, or a combination thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein PD-L1 protein is detected using IHC.

### Claim 18 (depends on 17)

The method of claim 17, wherein PD-L1 protein is detected using a diagnostic anti-PD-L1 antibody.

### Claim 19 (depends on 17)

The method of claim 17, wherein the IHC is performed using the Ventana Benchmark XT or Benchmark Ultra system.

### Claim 20 (depends on 13)

The method of claim 13, wherein the tumor tissue sample:
(a) further comprises tumor cells, stromal cells, or a combination thereof; and/or
(b) is formalin-fixed and paraffin-embedded, archival, fresh, or frozen.

### Claim 21

A method for treating a non-small cell lung cancer in an individual comprising
intravenously administering to the individual about 1200 mg of an anti-PD-L1 antibody every three weeks,
wherein the anti-PD-L1 antibody is MPDL3280A.

### Claim 22 (depends on 21)

The method of claim 21, wherein the anti-PD-L1 antibody is administered to the individual in combination with an effective amount of an additional therapeutic agent or an adjuvant.

### Claim 23 (depends on 22)

The method of claim 22, wherein:
(a) the additional therapeutic agent is carboplatin, etoposide, paclitaxel, or albumin-engineered nanoparticle formulation of paclitaxel (nab-paclitaxel); or
(b) the adjuvant is cisplatin.

### Claim 24 (depends on 21)

The method of claim 21, wherein prior to administration of the anti-PD-L1 antibody, the individual has been determined to be an individual who is likely to have an increased clinical benefit from treatment with an anti-PD-L1 antibody based on the presence of a detectable expression level of PD-L1 protein in tumor infiltrating immune cells covering ≥10% of tumor area in a tumor tissue sample obtained from the individual.

### Claim 25

A method for treating a metastatic non-small cell lung cancer in an individual comprising
intravenously administering to the individual about 1200 mg of an anti-PD-L1 antibody every three weeks,
wherein the anti-PD-L1 antibody is MPDL3280A.

### Claim 26 (depends on 25)

The method of claim 25, wherein the anti-PD-L1 antibody is administered to the individual in combination with an effective amount of an additional therapeutic agent or an adjuvant.

### Claim 27 (depends on 26)

The method of claim 26, wherein:
(a) the additional therapeutic agent is carboplatin, etoposide, paclitaxel, or albumin-engineered nanoparticle formulation of paclitaxel (nab-paclitaxel); or
(b) the adjuvant is cisplatin.

### Claim 28 (depends on 25)

The method of claim 25, wherein prior to administration of the anti-PD-L1 antibody, the individual has been determined to be an individual who is likely to have an increased clinical benefit from treatment with an anti-PD-L1 antibody based on the presence of a detectable expression level of PD-L1 protein in tumor infiltrating immune cells covering ≥10% of tumor area in a tumor tissue sample obtained from the individual.

### Claim 29

A method of treating a sarcoma in an individual comprising intravenously administering to the individual about 15 mg/kg of an anti-PD-L1 antibody every three weeks, wherein the anti-PD-L1 antibody is MPDL3280A.

### Claim 30 (depends on 29)

The method of claim 29, comprising administering to the individual about 1200 mg of the anti-PD-L1 antibody every three weeks.
